Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph not_applicable
4
100%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
N/ANon-phased studies
4(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A4 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye

NCT05062564
completednot_applicable

Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study

NCT03956225
completednot_applicable

A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice

NCT03708367
completednot_applicable

Lipiflow vs iLux Patient Acceptance and Comfort Study

NCT04454983

Clinical Trials (4)

Showing 4 of 4 trials
NCT05062564Not Applicable

Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye

Completed
NCT03956225Not Applicable

Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study

Completed
NCT03708367Not Applicable

A Post-Market Evaluation of LipiFlow Treatment in Cataract Surgery Practice

Completed
NCT04454983Not Applicable

Lipiflow vs iLux Patient Acceptance and Comfort Study

Completed

All 4 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
4